Kornimate/medical-research-clean huggingface dataset:
self selected exercise intensity in pad patients

Conditions: Peripheral Artery Disease

Summary: although the benefits of supervised walking training in patients with peripheral arterial disease (pad) and symptoms of intermittent claudication (ic) are well established, one of the main problems found in this type of protocol is low adherence to training, which is possibly related to pain during training. in addition, little is known about the impact of performing exercise with pain on cerebral blood flow and cardiovascular health indicators. thus, the objective of the present study will be to analyze the acute effects of walking exercise with self-selected intensity on the cardiovascular health indicators of patients with pad. therefore, 17 patients with pad will undergo three experimental sessions: exercise with self-selected intensity, exercise until maximum pain and control. the responses of the cardiovascular variables (heart rate variability, blood pressure, heart rate, arterial stiffness and endothelial function) will be obtained before and after the sessions. in addition, during the session cardiovascular responses (cerebral blood flow, blood pressure and heart rate), perceptual and affective responses, as well as information about the exercises performed during the session will be obtained. the responses before and after exercise will be analyzed using the two-way analysis of variance for repeated measures (anova) and the newman-keuls post-hoc test. the value of p \<0.05 will be considered significant.


Eligibility criteria:
inclusion criteria: * peripheral artery disease in one or both limbs (ankle brachial index \<0.9); * claudication symptoms in six-minute walking test; * who can walk at least 90 meters without interruption; * that have physical conditions to perform the exercise sessions; exclusion criteria: * do not finish three experimental sessions;

Keywords: peripheral artery disease exercise cerebral blood flow cardiovascular system
a study of intraperitoneal paclitaxel in combination with sox compared with sox alone in gastric cancer with malignant ascites

Conditions: Gastric Cancer; Stomach Neoplasms

Summary: this study is designed to compare the efficacy of intraperitoneal paclitaxel in combination with sox, with sox alone in the first-line treatment of gastric cancer with malignant ascites


Eligibility criteria:
inclusion criteria: * had a histologically proven adenocarcinoma of the gastroesophageal junction, or stomach that was locally advanced (inoperable) or metastatic * malignant ascites(over pelvic cavity in ct scan and confirmed by cytology) * an eastern cooperative oncology group performance status of 0 to 2 * adequate renal, hepatic, and hematologic function exclusion criteria: * previous chemotherapy or radiotherapy (unless in the adjuvant setting) * uncontrolled cardiac disease, or other clinically significant, uncontrolled * coexisting illness or previous or concurrent cancer * her2 positive and willing to use trastuzumab
infants of diabetic mothers: a cohort study

Conditions: Pregnancy in Diabetes; Fetal Complications

Summary: saudi arabia has been named by the international diabetes federation as among the top ten countries with highest prevalence of diabetes. women are said to have overall prevalence twice that for men. with high birth rate in the country we decided to look at the impact of diabetic pregnancies on their off-springs

diabetics are followed regularly in diabetic outpatient clinics where dietary and medical management are offered. diabetic pregnancies are managed by a team consisting of diabetologist, obstetrician, feto-maternal obstetrician and dietician. management of these pregnancies depends on whether these women have pre-gestational or gestational diabetes. very few diabetic women have exposure to preconceptual advice. for this reason we opted to find out the outcome of infants of diabetic mothers compared to those mothers who are essentially normal with no associated medical or obstetric disorders. equally we wanted to see if there are differences in the outcome of infants born to pre-gestational and gestational diabetic mothers.

Eligibility criteria:
inclusion criteria:all infants born to diabetic mothers * infants born to mothers with normal pregnancies exclusion criteria: * infants born to mothers with other medical disorders before or during pregnancy which may affect the newborn

Keywords: nicu
predictive risk factors for pancreatic fistula after pancreaticoduodenectomy

Conditions: Pancreas Cancer; Pancreas Neoplasm; Pancreatic Fistula; Pancreas Adenocarcinoma; Periampullary Cancer; Periampullary Carcinoma; Resectable Pancreatic Cancer

Summary: pancreaticoduodenectomy (pd) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality. postoperative pancreatic fistula (popf) is the most common and clinically significant complication following pd. in this study, the investigators aim to determine the predictive risk factors for clinically related postoperative pancreatic fistula (cr-popf) in the preoperative, intraoperative and postoperative period in patients that underwent pd. the total number of 100 participants expected to be included in this research who underwent pd between 2025 and 2026.

pancreaticoduodenectomy (pd) is a complex procedure performed in patients with malignant or benign tumors of the pancreatic head and periampullary region, associated with high morbidity and mortality rates. despite dramatic advancements in surgical techniques and perioperative management, reported morbidity and mortality rates following pd are 41.56% and 2.88%, respectively, which remain unsatisfactory. postoperative pancreatic fistula (popf) is the most common and clinically significant complication following pd. therefore, accurate and timely prediction of popf after pd is necessary to reduce secondary mortality from serious complications and optimize individual patient treatment decisions. this study aimed to determine the predictive risk factors for clinically related postoperative pancreatic fistula (cr-popf) in the preoperative, intraoperative and postoperative period in patients that underwent pd.

Eligibility criteria:
inclusion criteria: * patients with resectable distal common bile duct carcinoma, periampullary carcinoma, duodenal carcinoma, and carcinoma of the head of the pancreas. * patients meeting the curative treatment intent in accordance with clinical guidelines: * no evidence of metastasis. * radiological non-involvement of superior mesenteric vein \& portal vein. * american society of anesthesiologists (asa) scores i \& ii. * patients aged \> 18 years. * ability to understand and the willingness to sign a written informed consent document * agreement to complete the study exclusion criteria: * unfit patients for surgery due to severe medical illness. * inoperable patients with distant metastases, including peritoneal, liver, distant lymph node metastases, and involvement of other organs. * irresectable tumors in diagnostic laparoscopy. * history of other malignant disease. * pregnant or breast-feeding women. * patients with serious mental disorders. * patients with vascular invasion and requiring vascular resection as evaluated by the multidisciplinary team according to abdominal imaging data. * pancreatoduodenectomy for other diagnosis like cystic lesions, benign tumors or chronic calcific pancreatitis * patients refused to participate in the study.
induction tislelizumab combined with chemotherapy followed by definitive chemoradiotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma

Conditions: Immunotherapy Esophagus Cancer

Summary: to explore the efficacy of tislelizumab combined with chemotherapy in the treatment of locally unresectable esophageal squamous cell carcinoma (escc)


Eligibility criteria:
inclusion criteria: * histologically confirmed localized escc that is suitable for ccrt, including: stage ii-iva (ajcc version 8) inoperable escc (medically unfit for surgery or refusing surgical intervention);; * aged 18-70, both sexes; * ecog score 0-1 * the presence of measurable and/or nonmeasurable lesions that met the definition of recist1.1; * adequate organ and bone marrow function, meeting the following definitions: 1. blood routine (no blood transfusion, no granulocyte colony-stimulating factor \[g-csf\], and no other drugs were used within 14 days before treatment);absolute neutrophil count (anc) ≥1.5×109/l;hemoglobin (hb) ≥9.0 g/dl;platelet count (plt) ≥100×109/l; 2. blood biochemistry creatinine clearance rate ≥60 ml/min;total bilirubin (tbil) ≤ 1.5×uln;aspartate aminotransferase (ast) or alanine aminotransferase (alt) level ≤2.5×uln; * expected survival time \> 6 months; * fertile female subjects and male subjects with partners of reproductive age are required to use a medically approved contraceptive method during the study treatment period and for at least 3 months after the last treatment; * patients who volunteered to participate in this study and signed the informed consent form. exclusion criteria: * a history of fistula caused by primary tumor invasion; * presence of clinically uncontrolled pleural effusion, pericardial effusion, or ascites that required repeated drainage or medical intervention (within 2 weeks before randomization); * known intolerance or resistance to chemotherapy specified in the trial protocol; * have received any other escc antitumor therapy (e.g., therapy targeting pd-1, pd-l1, pd-l2 or other tumor immunotherapy, radiotherapy, targeted therapy, ablation or other systemic or local antitumor therapy); * patients with active autoimmune disease or a history of autoimmune disease that may relapse, or a known history of allogeneic organ transplantation or allogeneic hematopoietic stem cell transplantation; * history of interstitial lung disease, non-infectious pneumonia or uncontrolled systemic diseases, including pulmonary fibrosis and acute lung disease; * severe chronic or active infection (including tuberculosis infection) requiring systemic antimicrobial therapy, antifungal therapy or antiviral therapy before enrollment; * known history of hiv infection; * other malignancies (except cured basal cell carcinoma of the skin, carcinoma in situ of the breast and carcinoma in situ of the cervix) in the past 5 years; * received live vaccine within 28 days before enrollment; * while participating in another therapeutic clinical trial.
effect of whole-body photobiomodulation on muscular performance enhancement.

Conditions: Sports Performance; Injury Prevention; Muscle Damage; Musculoskeletal Pain

Summary: introduction: photobiomodulation therapy (pbmt) is based on the emission of light ranging from red to near-infrared spectra by different devices based on diode lasers or light-emitting diodes. these devices emitting different wavelengths can increase mitochondrial activity and energy synthesis (atp - adenosine triphosphate) that in turn can help to prevent muscle damage, decrease muscle fatigue and enhance muscle performance. thus, pbmt can be a promising therapeutic resource in the sports field. objectives: the aim of this study is to verify the effect of pbmt on the muscle performance and prevention of muscle damage and delayed onset muscle soreness (doms) in professional soccer players submitted to a muscle damage protocol. methodology: the present study is a randomized sham-controlled clinical trial following the spirit guidelines.

participants will be allocated into 3 balanced randomized groups, as follows: 1) pbmt post muscle damage protocol (pbmt-post); 2) pbmt pre (pbmt-pre) and 3) pbmt placebo (pbmt-sham). all groups will be submitted to a) anamnesis; b) measurement of blood levels of creatine phosphokinase (ck); c) delayed onset muscle soreness (doms); d) muscle performance tests (squat jump test (sj) and counter movement jump (cmj)); e) dynamometry of the knee extensor muscles. whole body pbmt will be applied according to the groups, during 10 min (sham or effective), with an effective dose of 13.85 j/cm2 and irradiance of 46.17 mw/cm2. muscle damage protocol will consist of 8 exercises for lower limb muscles, with 3 sets of 10 repetitions each, 1 minute of rest between sets, and 2 minutes of rest between exercises. next, participants will be evaluated for levels of ck, doms and muscle performance (sj, cmj, dynamometry) at 24, 48 and 72 hours after muscle damage protocol. data will be analyzed and compared between groups with a significance level of 5%.

Eligibility criteria:
inclusion criteria: * male individuals aged between 18 and 35 years, professional soccer players who engage in training at least 5 times a week, will be selected. data collection will be conducted at the desportivo brasil football club, located in porto feliz, são paulo. the sample will consist of team members, with a total of 36 athletes established to compose the sample. all data collection will take place in the same location. exclusion criteria: * individuals with any impediment to physical activity or those presenting dysfunctions that may impair the neuromuscular system will be excluded.

Keywords: phototherapy laser therapy muscle fatigue muscle damage
bruxism and parafunctional oral habits in children and adolescents with cerebral palsy

Conditions: Cerebral Palsy; Bruxism

Summary: the aim of the study is to evaluate and analyze the rates and relationships between bruxism, other parafunctional oral activities, and oral-motor activities in children and adolescents with spastic cp.

this cross-sectional study was conducted on children and adolescents with cp receiving care services in three different private rehabilitation centers between january 2020 and march 2021. all the parents or primary caregivers included in the study were mothers of children with cp. initially, information about bruxism and parafunctional oral habits and the study's aims were given to the mothers. all the mothers provided written informed consent for voluntary participation. 63 children and adolescents with spastic cp were analyzed, comprising 35 girls and 28 boys. all the children were observed in clinical environments for classification according to the gross motor function classification system (gmfcs) and levels of activity and communication. data were collected from an evaluation form, clinical examination of the individuals, and interviews with the mothers. in the first section of the evaluation, the medical records of the children with cp were reviewed for demographics, and clinical data, including age, gender, cp type, medication, and history of epilepsy. the gmfcs was used to determine the level of impairment in gross motor functions of the children. in the second section of the evaluation, bruxism and other parafunctional oral activities were evaluated in detail through a face-to-face interview with each child's mother. other parafunctional oral habits were both questioned and observed in the clinical environment. the presence of sucking habits (thumb sucking, lip-biting, nail-biting, and cheek biting) and the use of a pacifier for more than 24 months was noted and recorded as present or absent. the tongue-thrust reflex evaluation scale was applied for tongue thrust. swallowing problems were evaluated with the water swallowing test, drooling with the saliva control problem severity, and frequency scale. the habit of chronic breathing through the mouth was evaluated through information gained from the mother and from observation of whether nasal or buccal breaths were taken during routine treatment and evaluation in the clinical environment. for the evaluation of chewing problems, information about feeding was obtained from the mother and recorded as difficulty in chewing solid food, otherwise as absent.

Eligibility criteria:
inclusion criteria: * children and adolescents with a diagnosis of spastic cp. * children and adolescents ages between 3-18 years old. exclusion criteria: * children and adolescents with a diagnosis of dyskinetic, ataxic, and/or mixed type cp * were aged \<3 years or ≥19 years, * had severe sight or hearing impairment, or had received any orthodontic treatment

Keywords: cerebral palsy children adolescent bruxism habits
use of a microbial sealant to reduce surgical site infections.

Conditions: Surgical Site Infection; SCIP

Summary: surgical site infections (ssi) are costly complications that may cause significant morbidity and increase the cost of care, particularly in colorectal surgery. microbial sealants (ms) are a new class of wound barriers aimed at decreasing ssi, however there is only evidence of benefit in clean class 1 procedures. based on its success in class 1 procedures, we hypothesized that a microbial sealant could reduce the rate of ssi by half for clean contaminated colorectal procedures (class 2).


Eligibility criteria:
inclusion criteria: 1. nonemergent colon and/or rectal abdominal surgical procedures 2. women of child-bearing potential must have a negative serum hcg assay prior to surgery 3. ages ≥18 years. exclusion criteria: 1. known history of hypersensitivity to cyanoacrylate, formaldehyde or acetone products. 2. undergoing emergency surgery (urgent surgery is allowed if informed consent is obtained and the study procedures can be performed). emergency surgery includes cases where standard bowel preparation and other preoperative assessments cannot be done. 3. undergoing a significant concomitant surgical procedure (e.g., whipple \& organ transplant surgery). the following concomitant procedures are allowed: appendectomy, cholecystectomy, oophorectomy, liver biopsy/wedge resection (but not liver resection), cystectomy. 4. history of prior laparotomy within the last 60 days of this planned procedure. 5. planned to undergo a second laparotomy or colorectal surgical procedure (e.g. colostomy or ileostomy takedown) within 60 days of this planned first procedure. 6. evidence preoperatively of any of the following: sepsis, severe sepsis, or septic shock (note that sirs alone is not an exclusion criteria).6, 7 7. preoperative severe neutropenia defined as total neutrophil count ≤500 × 106/l. 8. current abdominal wall infection/surgical site infection from previous laparotomy/laparoscopy or for any reason. 9. receiving antibiotic therapy within the 1 week prior to the date of surgery. 10. preoperative evaluation suggests intra-abdominal process that might preclude full closure of the skin. 11. preoperative serum creatinine \> 3 mg/dl or renal failure requiring dialysis. 12. history of ongoing treatment (e.g. chemotherapy, radiation) for non-colorectal cancer. 13. history of major organ transplantation, including bone marrow transplantation. 14. taking systemic steroids \>10 mg prednisone daily or remicade within 2 weeks prior to surgery or a history of a current immunosuppressive condition (eg, symptomatic hiv infection), defined as a cd4 count \< 200. 15. pregnant, lactating, or of childbearing potential not practicing a birth control method with a high degree of reliability (defined in section 3.1). 16. participation within 30 days before the start of this study in any experimental drug or device study, or currently participating in a study in which the administration of investigational drug or device within 60 days is anticipated.
assessing the relationship between symptoms and mitral regurgitnant. severity

Conditions: Mitral Insufficiency

Summary: the current american college of cardiology/american heart association (acc/aha) guidelines recommend surgery in patient with mitral regurgitation (mr) based on 1) the severity of mr and 2) the presence or absence of symptoms. studies have shown that cardiovascular magnetic resonance (cmr) is an accurate method to quantify the severity of mr. however, studies have also shown that symptoms are not necessarily related to the presence of symptoms. thus, there appears to be a disconnect between the severity of mr and symptoms. recent analysis of our data has shown that females and older patients with smaller ventricles, lower stroke volumes, and lower regurgitant volume relative to regurgitant fraction tend to be symptomatic. these findings suggest that decreased left ventricular compliance, i.e. diastolic dysfunction, may play an important role as an etiology of symptoms in patients with mitral regurgitation. the aim of this study is to study the presence of diastolic dysfunction in patients with mr and its association with symptom burden and exercise capacity.

the study is an observational study of patients with mitral regurgitation undergoing lhc prior to mitral valve surgery or percutaneous mitral valve intervention. prior to patients lhc they will undergo testing using cmr, cpet, and kccq. during the lhc, patients will undergo evaluation of intracardiac pressures and volumes using a specialized catheter which measures pressure and volume changes throughout the cardiac cycle. cmr- cmr evaluation will quantify mitral regurgitant volume and fraction, right and left atrial size and function, and myocardial scar quantification. cpet- objectively assess patients exercise capacity. kccq- is a standard questionnaire designed to assesses patients quality of life and symptom burden. lhc- pressure-volume loops will be measured during lhc. this will quantify left ventricular compliance and assess patients for the presence of diastolic dysfunction. these evaluations will help us better understand the relationship between symptoms, exercise capacity, severity of mr and diastolic dysfunction.

Eligibility criteria:
inclusion criteria: * age \>=18 years of age * able to give informed consent * primary (degenerative) mitral regurgitation * lvef \>=50% * undergoing cardiac catheterization * able to exercise on a treadmill exclusion criteria: * unable to give informed consent * secondary (functional) mitral regurgitation * lvef \<50% * known coronary artery stenosis \>=70% or past revascularization * more than mild aortic stenosis, mitral stenosis, aortic regurgitation, tricuspid regurgitation, or pulmonic regurgitation * hypertrophic cardiomyopathy * pregnancy

Keywords: mitral regurgitation symptoms exercise capacity
use of eylea for the treatment of an optic nerve hemangioma

Conditions: Retinal Hemangioma

Summary: this is a single patient investigative treatment study. the patient was diagnosed with a retinal tumor in one eye. in the last 2 years, the patient has been treated with all available and conventional therapies, including intraocular injections of avastin and lucentis, steroids, and photodynamic therapy. any positive results were short-term, and caused an eventual decline in central vision. aflibercept has been shown to be effective against the growth of new vessels, secondary to macular degeneration. this study proposes that it may also be more effective in treating this particular patient and case. the study treatment plan is for 6 months initially, with the intention to continue treatment.

the treatment plan will be to administer aflibercept 2.0 mg intravitreally every two to four weeks for at least six consecutive injections. prior to initiation of therapy and at each study visit, a full ophthalmic examination, best-corrected visual acuity, and a complete review of systems to monitor for any toxicity will be performed. in addition, the investigators will perform fluorescein and indocyanine green angiography at baseline and obtain color fundus photographs as well as spectral domain oct images to properly document the extent and degree of activity of the vascular tumor at baseline and at all study visits.

Eligibility criteria:
inclusion criteria: * retinal hemangioma * previously treated with conventional therapies, including avastin, lucentis, steroid, and photodynamic therapy, with less than ideal results exclusion criteria: * ongoing reevaluation of adverse events, including inflammation, elevated intraocular pressure, or any suspected toxicity from aflibercept